DPP4 and fatty liver disease: The present study aimed to investigate the effects of pemafibrate (a selective proliferator-activated receptor-α agonist) vs. weight loss through intensive lifestyle modification on hepatic steatosis and fibrosis evaluated by FibroScan and on serum levels of soluble Dipeptidyl Peptidase-4 (sDDP-4)/CD26, a hepatokine, in people with type 2 diabetes and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).